Marshall Wace
PGNX

Marshall Wace’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Marshall Wace’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13,985
Closed -$58K – 2209
2018
Q4 		$58K Buy
+13,985
New +$71.2K ﹤0.01% 1434
2015
Q3 		– Sell
-20,567
Closed -$153K – 1117
2015
Q2 		$153K Hold
20,567
– – ﹤0.01% 831
2015
Q1 		$123K Hold
20,567
– – ﹤0.01% 766
2014
Q4 		$155K Sell
20,567
-148,090
-88% -$886K ﹤0.01% 761
2014
Q3 		$875K Buy
+168,657
New +$840K 0.01% 568

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Marshall Wace's PGNX Position: Q1 2019 in Review

Marshall Wace sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2019, closing a stake of 13,985 shares — an estimated $58K sold.

Marshall Wace first reported a position in PGNX in Q3 2014 and held it in 5 quarters. The position peaked at $875K in Q3 2014. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

  • Marshall Wace reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
  • Marshall Wace sold 13,985 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $58K.
  • Marshall Wace first reported a position in Progenics Pharmaceuticals Inc in Q3 2014 and held it in 5 quarters.
  • Marshall Wace's Progenics Pharmaceuticals Inc position peaked at $875K in Q3 2014.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on Marshall Wace's 13F filing for Q1 2019, filed 14 May 2019.